Overview

COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers

Status:
Not yet recruiting
Trial end date:
2022-05-19
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the safety and tolerability of co-formulated subcutaneous (SC) and intravenous (IV) casirivimab+imdevimab The secondary objectives of the study are to: - Explore variability in the drug concentration profiles of casirivimab and imdevimab after co-formulated subcutaneous (SC) or intravenous (IV) administration - Characterize the immunogenicity of casirivimab and imdevimab in serum over time
Phase:
Phase 1
Details
Lead Sponsor:
Regeneron Pharmaceuticals